Navigation Links
Next Safety, Inc.'s Innovative Drug Delivery System Will Replace,Cigarettes and Significantly Advance Pulmonary Medication Delivery

WEST JEFFERSON, N.C.--(BUSINESS WIRE)--Jun 15, 2007 - Next Safety, Inc. has identified basic scientific mechanisms that promise to revolutionize pulmonary drug delivery. This proprietary technology uses a stream of purified air to deliver medications deep into the pulmonary system. It is considered superior to other drug delivery systems because it rapidly administers aerosolized drugs to the lining of the lungs at previously unrealized efficiencies. The delivery technique has multiple applications across many therapeutic areas, such as asthma and nicotine replacement. Preliminary findings indicate that the Next Safety device delivers nicotine more efficiently than cigarettes, but without the negative effects of smoke.

According to estimates by the World Health Organizations smoking kills 5 million people globally each year. In 20 years, smoking will kill more than 10 million people per year. Half of the 1.3 billion smokers in the world today (650 million) will die from their habit.

"Our technology will save more lives than have been lost in all the wars in recorded history" - C. Eric Hunter, CEO and Founder of Next Safety, Inc.

"The fundamental nature of this development means that pulmonary delivery for a wide range of drug classes will be vastly improved or enabled," said Tom Stern, MD, assistant professor of medicine in the Department of Internal Medicine at Carolinas Medical Center and member of Next Safety's Medical Advisory Board. "To date laboratory data suggests applications such as childhood asthma or home delivery of medicines previously requiring an IV will be equally benefited. Although further testing is needed, this fundamental breakthrough may eventually be seen as important as the invention of the syringe."

"We've taken a fresh approach to pulmonary drug delivery," said Lyndell Duvall, director of technology & product development for Next Safety, Inc. "By obeying mother nature, and borrowing techniques and materials from the semiconductor industry, we are able to individually generate each droplet in an aerosol and dictate how it will behave before it is delivered to the patient."

The company is planning clinical testing under an IRB protocol that will include antibiotics, phenergan, albuterol, tobramycin, and morphine. The tests will be conducted in coordination with Carolinas Medical Center, located in Charlotte, NC. Early results should be available July 07'.

Next Safety is located in North Carolina, an area already known for leadership in technology and medicine. The company has leveraged this expertise to develop the worlds most advanced respirator technology and to advance the field of pulmonary medicine. Next Safety's bPure8000(TM) line of respirators provide higher protection against airborne viruses and fine particulate air pollution than any other respirator available globally. Next Safety now brings the same innovative approach to the science of pulmonary drug delivery and nicotine replacement.

For more information about Next Safety, Inc. visit www.nextsafety.com.

Contact

Next Safety, Inc.
Bethany Swaim, 336-246-7700


'"/>




Related medicine technology :

1. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
2. Bionovos MF101 Shows Positive Safety, Tolerability and Efficacy in Phase 2 Trial
3. Oncolytics Biotech Inc.s Research Collaborators to Present REOLYSIN Clinical Trial Data at ASCO Conference
4. Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
5. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
6. DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy
7. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
8. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
9. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
10. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
11. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 According to a ... (Standard Pen Needles, Safety Pen Needles), Needle Length (4mm, ... Hormone), Mode of Purchase (Retail, Non-Retail) - Trends & ... studies the market for the forecast period of 2016 ... 2.81 Billion by 2021 from USD 1.65 Billion in ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
Breaking Medicine News(10 mins):